EUVIMEDEUVIMED entdecken
Crossref

Discovery of Novel Glutaminase (GLS1) and Histone Deacetylase (HDAC) Dual Inhibitors as a Promising Strategy for Cancer Therapy

Zhisheng Zhang, Xuan Zhang, Yinan Jiang, Manqi Zhang, Juan Zhao, Tianxin Li, Jiani Yang, Shengnan Shi, Xueling Cao, Lingxiang Jiang, Zihan Tian, Yongsheng Wu und 7 weitere

Journal of Medicinal Chemistry · 2026

DOI: 10.1021/acs.jmedchem.6c01288 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Zhisheng Zhang und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing211198, P. R. China. Hauptthemen laut MEDLINE: Glutaminase, Histone Deacetylase Inhibitors, Antineoplastic Agents, Histone Deacetylases. Die Arbeit nennt 43 Literaturangaben. Gefördert von: National Natural Science Foundation of China (NSFC), Natural Science Foundation of Jiangsu Province, Fundamental Research Funds for the Central Universities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glutaminase 1 (GLS1) and histone deacetylases (HDACs) are important targets involved in cancer metabolism and epigenetic regulation, respectively. Herein, we report the design, synthesis, and biological evaluation of first-in-class GLS1/HDAC dual inhibitors as a single-molecule strategy for cancer therapy. Through systematic structure-activity relationship studies and biochemical profiling, compound 58 was identified as a promising dual inhibitor with moderate GLS1 inhibition and potent HDAC activity, particularly against HDAC6. Compound 58 exhibited strong antiproliferative activity in multiple cancer cell lines and modulated GLS1-associated glutamine metabolism and HDAC-related acetylation markers in cells. In a CT26 tumor-bearing mouse model, compound 58 achieved a tumor growth inhibition (TGI) rate of 91.10% without obvious systemic toxicity. Overall, this study supports GLS1/HDAC dual inhibition as a promising anticancer strategy and provides compound 58 as a valuable lead for further optimization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlutaminaseHistone Deacetylase InhibitorsAntineoplastic AgentsHistone DeacetylasesDrug DiscoveryEnzyme InhibitorsHumansAnimalsStructure-Activity RelationshipMiceCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorNeoplasms

Stichwörter der Autor:innen

GLS1HDACantitumordual-target inhibitors

Substanzen

GlutaminaseHistone Deacetylase InhibitorsAntineoplastic AgentsHistone DeacetylasesEnzyme Inhibitors

Autor:innen und Institutionen

  • Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing211198, P. R. China.
  • Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing211198, P. R. China.
  • Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing210006, P. R. China.

ORCID-Profile: Jinlei Bian, Zhiyu Li, Xi Xu

Förderung

  • National Natural Science Foundation of China (NSFC)
  • Natural Science Foundation of Jiangsu Province
  • Fundamental Research Funds for the Central Universities
  • National College Students Innovation and Entrepreneurship Training Program
  • Youth Science and Technology Talent Support Program of Jiangsu Province

Zitieren

APA

Zhang, Z., Zhang, X., Jiang, Y., Zhang, M., Zhao, J., Li, T., Yang, J., Shi, S., Cao, X., Jiang, L., Tian, Z., Wu, Y., Ru, J., Zhu, L., Du, Q., Bian, J., Li, Z., Xu, X., & Wang, J. (2026). Discovery of Novel Glutaminase (GLS1) and Histone Deacetylase (HDAC) Dual Inhibitors as a Promising Strategy for Cancer Therapy. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c01288

Vancouver

Zhang Z, Zhang X, Jiang Y, Zhang M, Zhao J, Li T, et al. Discovery of Novel Glutaminase (GLS1) and Histone Deacetylase (HDAC) Dual Inhibitors as a Promising Strategy for Cancer Therapy. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.6c01288

BibTeX
@article{Zhang2026,
  author = {Zhang, Zhisheng and Zhang, Xuan and Jiang, Yinan and Zhang, Manqi and Zhao, Juan and Li, Tianxin and Yang, Jiani and Shi, Shengnan and Cao, Xueling and Jiang, Lingxiang and Tian, Zihan and Wu, Yongsheng and Ru, Jiawen and Zhu, Liuxiang and Du, Qianming and Bian, Jinlei and Li, Zhiyu and Xu, Xi and Wang, Jubo},
  title = {Discovery of Novel Glutaminase (GLS1) and Histone Deacetylase (HDAC) Dual Inhibitors as a Promising Strategy for Cancer Therapy},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  doi = {10.1021/acs.jmedchem.6c01288}
}
Kostenlos starten →